Evidence map›Paper›PMID 42898736›Full record

ReviewFrontiers in endocrinology2026

Endocrine determinants of MASLD: mechanisms and therapeutic targets.

Richa Chaturvedi, Anu Mathew, Aprajita Pradhan, Monika Goyal, Monika Sharma, Varsha Kachroo, Chhavi Agrawal, Aishwarya Krishnamurthy, Surabhi Atreja, Ashish Atreja

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Richa ChaturvediAdvance Centre for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital, Delhi, India.
Anu MathewDepartment of Endocrinology, Fortis Hospital, Gurugram, Haryana, India.
Aprajita PradhanDepartment of Endocrinology, Max Superspecialty Hospital, Dwarka, Delhi, India.
Monika GoyalDepartment of Endocrinology, Yatharth Super Speciality Hospital, New Delhi, India.
Monika SharmaDepartment of Endocrinology, Aakash Hospital, Dwarka, Delhi, India.
Varsha KachrooAdvance Centre for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital, Delhi, India.
Chhavi AgrawalDepartment of Endocrinology, Fortis Escorts Heart Institute, Delhi, India.
Aishwarya KrishnamurthyDepartment of Endocrinology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh, India.
Surabhi AtrejaDivision of Cardiovascular Medicine, UC Davis Medical Center, Sacramento, CA, United States.
Ashish AtrejaDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Redwood, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults worldwide, yet is still framed largely as a hepatological disorder despite being driven substantially by endocrine and metabolic dysfunction. This review proposes a unified endocrine framework organised around seven hormonal axes, presenting each in terms of molecular pathogenesis, clinical presentation, and therapeutic implications. Insulin resistance is the central driver, coupling chronic caloric excess to hepatic

Indexed as

Endocrine SystemFatty LiverAnimalsHumansInsulin ResistanceadipokinesGH/IGF-1glucocorticoidsgut-liver axishypogonadismincretinsinsulin resistanceMASH

Identifiers

PMID42898736
PMCPMC13678635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.